Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: CPPGroup rises as agrees sale of India business

23rd Jul 2025 11:01

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.

----------

AIM - WINNERS

----------

CPPGroup PLC, up 26% at 162.00 pence, 12-month range 70.00p-171.00p. The Leeds, England-based technology-driven assistance and insurance provider agrees terms for the disposal of its business in India, CPP Assistance Services Private Ltd, for USD21.0 million in cash. CPP India will be sold to OneAssist Consumer Solutions Private Ltd and Bolttech Device Protection India Private Ltd. Of the total price tag, USD15.8 million is payable upon completion, with the remainder to be paid in two equal instalments six and twelve months after completion. CPP India reported pretax profit of GBP4.7 million in 2024 and contributed GBP6.6 million to group earnings before interest, tax, depreciation and amortisation of GBP1.4 million. CPPGroup expects the sale to result in a gain on disposal of around GBP10 million in 2025. "The sale of CPP India marks another key milestone in our strategic transformation," says Chief Executive Officer Simon Pyper. "Alongside the earlier disposal of CPP Turkey, this deal simplifies the group and strengthens our ability to accelerate investment in Blink." Blink is the firm's 'insurtech' division. The sale of CPP India is subject to shareholder approval

----------

Shield Therapeutics PLC, up 16% at 4.13p, 12-month range 1.60p-5.87p. The Newcastle, England-based commercial-stage pharmaceutical company says it is on track to turn free cash flow positive by the end of the year, as it reports a sharp rise in revenue for the second quarter of 2025. Revenue surges 86% on-year to USD12.8 million from USD6.9 million. It doubles on-quarter from USD6.4 million. Total prescriptions of its Accrufer iron deficiency drug rises 28% to 47,000 from 36,800 in the first quarter. The average net selling price rises on-quarter to USD231 from USD187.

----------

AIM - LOSERS

----------

CyanConnode Holdings PLC, down 4.5% at 7.76p, 12-month range 7.00p-15.00p. The Cambridge, England-based developer of narrowband radio frequency mesh networks posts a pretax loss of GBP3.7 million for the year to March 31, narrowed from GBP4.2 million the year before. The is largely due to a one-off GBP791,000 intangible assets impairment in financial 2024. Revenue declines 24% to GBP14.2 million from GBP18.7 million, with CyanConnode blaming election-related uncertainty in India and short-term consumer resistance to smart metering, which the firm does not expect to recur. Its order book more than triples to GBP180 million from GBP50 million. "In light of the inherent challenges in forecasting revenue timing in large infrastructure projects, the board has adopted a more conservative approach to its forecasting. To enhance transparency and help stakeholders track operational progress, going forward CyanConnode intends to provide quarterly updates on business progress," says Chief Executive Officer John Cronin.

----------

By Emily Parsons, Alliance News reporter

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

CppgroupShield TheraCyanconnode
FTSE 100 Latest
Value9,061.49
Change37.68